Press Releases
[Nov 2008] PolyTherics Strengthens Board with Non-Executive Director Appointment
PolyTherics Ltd., the biopharmaceuticals company commercialising technologies that prolong the half-life of proteins to optimise their therapeutic usefulness, is pleased to announce the appointment of Professor Simon Best as a Non-Executive Director to the Board.
[Nov 2008] PolyTherics to Present Therapeutic Protein Optimisation Platform at BIO-Europe Meeting
PolyTherics, the biopharmaceuticals company dedicated to precision engineering of protein half-life, will be announcing exciting new technology developments at the upcoming BIO-Europe 2008 conference in Mannheim, Germany on Wednesday, 19th November.
[Jun 2008] PolyTherics Ltd and Alligator Bioscience AB announce strategic collaboration for optimisation of next generation biopharmaceuticals
PolyTherics Ltd ("PolyTherics"), a biopharmaceutical company specialised in the targeted application of polymers to biopharmaceuticals, and Alligator Bioscience AB ("Alligator"), a biotechnology company applying proprietary technology to the improvement of proteins, today announced the establishment of a new alliance.
[May 2008] Secretary of State John Denham visits PolyTherics
Secretary of State John Denham, met Dr. Penny Bryant; a Senior Scientist, as well as Dr. Keith Powell, CEO of PolyTherics, at LBIC. Penny is seen explaining the advantages of PolyTherics TheraPEG™ technology.
[May 2008] Novel Approach to Drug Insolubility strengthens PolyTherics patent estate
London, UK. Polytherics Ltd ("PolyTherics"), a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy that specialises in the targeted application of polymers to biopharmaceuticals, today announced the grant of a European patent on the application of polymer complexation technology to improve drug efficacy. The technology represents a novel method of formulating poorly soluble drugs as solid dosage forms while also providing a means of reducing their systemic toxicity.
[Mar 2008] PolyTherics expands Collaboration with Biocompatibles and grants Option for Product Commercialisation Licences
PolyTherics Ltd ("PolyTherics"), a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy that specialises in the targeted application of polymers to biopharmaceuticals, today announced the expansion of its collaboration with Biocompatibles International plc ("Biocompatibles"), a leading medical technology company in the field of drug device combination products.
[Feb 2008] PolyTherics and Celtic Pharma sign Collaboration Agreement to explore technologies for improved drug performance
PolyTherics Limited ("PolyTherics"), a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy, and Celtic Pharma Development Services Bermuda Ltd ("Celtic Pharma"), a subsidiary of Celtic Pharmaceutical Holdings LP, a global private equity investment fund focused on the biopharma industry, today announced that they have entered into a broad research collaboration agreement.
[Feb 2008] New Consortium announces Significant Grant Funding of Anaemia product programme
GlycoForm Ltd, PolyTherics Ltd, and Aston University today announced that they have been awarded prestigious grants totalling £685,000 from the Technology Strategy Board and Biotechnology and Biological Sciences Research Council. This consortium is to use this additional funding over the next two years to accelerate the development of a treatment for anaemia initiated by GlycoForm.
